Evidence map›Paper›PMID 37695054›Full record

ArticleJournal of virology2023

PARP12 is required to repress the replication of a Mac1 mutant coronavirus in a cell- and tissue-specific manner.

Catherine M Kerr, Srivatsan Parthasarathy, Nancy Schwarting, Joseph J O'Connor, Jessica J Pfannenstiel, Emily Giri, Sunil More, Robin C Orozco, Anthony R Fehr

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. NADThe Journal of general virology · 2026
    Review
  3. An autoimmunity-associated allele ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Article
  6. An Autoimmunity-associated allele ofbioRxiv : the preprint server for biology · 2025
    Article
  7. Article
  8. Article
  9. The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.bioRxiv : the preprint server for biology · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. PARP12-mediated mono-ADP-ribosylation as a checkpoint for necroptosis and apoptosis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Article
  16. IFN-bioRxiv : the preprint server for biology · 2025
    Article
  17. Article
  18. Article
  19. Mutation of a highly conserved isoleucine residue in loop 2 of severalbioRxiv : the preprint server for biology · 2024
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Catherine M KerrDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Srivatsan ParthasarathyDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Nancy SchwartingDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Joseph J O'ConnorDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Jessica J PfannenstielDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Emily GiriDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Sunil MoreDepartment of Veterinary Pathology, Oklahoma State University , Stillwater, Oklahoma, USA.
Robin C OrozcoDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.
Anthony R FehrDepartment of Molecular Biosciences, University of Kansas , Lawrence, Kansas, USA.ORCID 0000-0003-1560-1573
University of Kansas · USOklahoma State University · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI KIM, HYUNJOON · 2016 to 2025
$23.9M
Graduate Training at the Biology-Chemistry InterfaceT32GM132061 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Brian Douglas Ackley · 2020 to 2026
$2.9M
Determining mechanisms of innate immune modulation by ADP-ribosylationR35GM138029 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Anthony R Fehr · 2020 to 2026
$2.7M
Investigating How ADP-ribosylation Impacts Innate Immunity During Coronavirus InfectionK22AI134993 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI FEHR, ANTHONY R · 2019 to 2020
$270k
NCI NIH HHS P30 CA168524NIAID NIH HHS K22 AI134993NIGMS NIH HHS P20 GM113117NIGMS NIH HHS R35 GM138029NIGMS NIH HHS T32 GM132061
6 · The paper itself

Abstract

ADP-ribosyltransferases (ARTs) mediate the transfer of ADP-ribose from NAD

Indexed as

Genes, ViralMurine hepatitis virusMutationPoly(ADP-ribose) PolymerasesVirus ReplicationAnimalsCell LineCoronavirus InfectionsDisease Models, AnimalInterferonsMiceMice, KnockoutOrgan SpecificityInterferonsPARP12 protein, mousePoly(ADP-ribose) PolymerasesADP-ribosylationcoronavirusmacrodomainMHVPARPpathology

Identifiers

PMID37695054
PMCPMC10537751
OpenAlexW4386591874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.